BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, Christensen E, Giustina G, Noventa F. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1994;21:656-666. [PMID: 7814813 DOI: 10.1016/s0168-8278(94)80115-0] [Cited by in Crossref: 201] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, Shaw G, Bell SJ, Desmond PV, Thompson AJ. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. World J Hepatol. 2017;9:48-56. [PMID: 28105258 DOI: 10.4254/wjh.v9.i1.48] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
2 Kubo S, Hirohashi K, Yamazaki O, Matsuyama M, Tanaka H, Horii K, Shuto T, Yamamoto T, Kawai S, Wakasa K. Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World J Surg. 2002;26:555-560. [PMID: 12098045 DOI: 10.1007/s00268-001-0267-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
3 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
4 Deng YR, Yoshida K, Jin QL, Murata M, Yamaguchi T, Tsuneyama K, Moritoki Y, Niu JQ, Matsuzaki K, Lian ZX. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol 2014;176:102-11. [PMID: 24372395 DOI: 10.1111/cei.12259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
5 Abbas Z, Abbas M, Abbas S, Shazi L. Hepatitis D and hepatocellular carcinoma. World J Hepatol 2015;7:777-86. [PMID: 25914778 DOI: 10.4254/wjh.v7.i5.777] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
6 Tarantino G, Citro V, Esposito P, Giaquinto S, de Leone A, Milan G, Tripodi FS, Cirillo M, Lobello R. Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins. BMC Gastroenterol. 2009;9:21. [PMID: 19292923 DOI: 10.1186/1471-230x-9-21] [Cited by in Crossref: 60] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
7 Abdela J. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag. Clin Med Insights Blood Disord 2019;12:1179545X19875105. [PMID: 31673229 DOI: 10.1177/1179545X19875105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
9 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol. 2007;13:125-140. [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
10 Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, Janssen HLA. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol 2020;5:406-17. [PMID: 32057301 DOI: 10.1016/S2468-1253(19)30344-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
11 Leemans W, Janssen HL, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol. 2007;13:2554-2567. [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
12 Bolukbas C, Bolukbas FF, Kendir T, Akbayir N, Ince AT, Abut E, Horoz M, Dalay AR, Sokmen MH, Ovunc O. The effectiveness of lamivudine treatment in cirrhotic patients with HBV precore mutations: a prospective, open-label study. Dig Dis Sci. 2006;51:1196-1202. [PMID: 16944009 DOI: 10.1007/s10620-006-8032-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
13 Zhang Y, Xie Y, Chen Q, Chen X, Dong Z, Tan X. Prevalence and co-infection of schistosomiasis/hepatitis B among rural populations in endemic areas in Hubei, China. Trans R Soc Trop Med Hyg 2020;114:155-61. [PMID: 31722017 DOI: 10.1093/trstmh/trz086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, Ben Ari Z, Braun M, Mitrut P, Yang SS, Akdogan M, Pirisi M, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Afdhal N. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019;70:1336-1348. [PMID: 30762895 DOI: 10.1002/hep.30561] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 29.0] [Reference Citation Analysis]
15 Klein MB, Baril JG, Charron MA, Fortin C, Lalonde R, Matte MF, Poliquin M, Talbot A, Therrien R, Tremblay C, Trottier B, Tsarevsky I, Villeneuve JP. Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol 2011;22:88-96. [PMID: 22942885 DOI: 10.1155/2011/686918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Myers RP, Shaheen AA, Faris P, Aspinall AI, Burak KW. Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list. PLoS One 2013;8:e51926. [PMID: 23349678 DOI: 10.1371/journal.pone.0051926] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
17 Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M. Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. Liver Cancer 2019;8:203-17. [PMID: 31192156 DOI: 10.1159/000489833] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
18 Farrell C, Hayes SC, Wire M, Zhang J. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. Br J Clin Pharmacol 2014;77:532-44. [PMID: 24117976 DOI: 10.1111/bcp.12244] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
19 Honda K, Seike M, Maehara S, Tahara K, Anai H, Moriuchi A, Muro T. Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis. World J Gastroenterol. 2012;18:2586-2590. [PMID: 22654459 DOI: 10.3748/wjg.v18.i20.2586] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
20 Yerke J, Bauer SR, Bass S, Torbic H, Militello M, Roach E, Hanouneh I, Welch S. Effectiveness of venous thromboembolism prophylaxis in patients with liver disease. World J Hepatol 2019;11:379-90. [PMID: 31114642 DOI: 10.4254/wjh.v11.i4.379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
21 Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Makuch R, Rendon G; Portal Hypertension Collaborative Group. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol. 2009;7:689-695. [PMID: 19281860 DOI: 10.1016/j.cgh.2009.02.021] [Cited by in Crossref: 136] [Cited by in F6Publishing: 114] [Article Influence: 11.3] [Reference Citation Analysis]
22 Babić Z, Bilić A, Babić D, Jagić V, Nikolić B, Sunić M. Predictive role of serum procollagen III peptide and Knodell's index in survival prognosis of patients with hepatitis B virus liver cirrhosis. Wien Klin Wochenschr 2003;115:302-8. [PMID: 12793031 DOI: 10.1007/BF03040336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, Jiao J, Wang JB. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol. 2015;21:7869-7876. [PMID: 26167087 DOI: 10.3748/wjg.v21.i25.7869] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
24 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 114] [Article Influence: 10.7] [Reference Citation Analysis]
25 Kim NH, Kim HJ, Cho YK, Hong HP, Kim BI. Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization. J Korean Med Sci 2019;34:e208. [PMID: 31373186 DOI: 10.3346/jkms.2019.34.e208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Tsai NC, Holck PS, Wong LL, Ricalde AA. Seroepidemiology of hepatitis B virus infection: analysis of mass screening in Hawaii. Hepatol Int 2008;2:478-85. [PMID: 19669323 DOI: 10.1007/s12072-008-9103-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
27 Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol. 2013;19:6849-6856. [PMID: 24187460 DOI: 10.3748/wjg.v19.i40.6849] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med. 2014;4:a024935. [PMID: 25359547 DOI: 10.1101/cshperspect.a024935] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
29 de Bruyn G, Graviss EA. A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. BMC Med Inform Decis Mak 2001;1:6. [PMID: 11806763 DOI: 10.1186/1472-6947-1-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
30 Honda K, Seike M, Murakami K. Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis. World J Hepatol 2015;7:2404-10. [PMID: 26464756 DOI: 10.4254/wjh.v7.i22.2404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
31 Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46:420-426. [PMID: 10673308 DOI: 10.1136/gut.46.3.420] [Cited by in Crossref: 264] [Cited by in F6Publishing: 218] [Article Influence: 12.6] [Reference Citation Analysis]
32 Shen L, Li JQ, Zeng MD, Lu LG, Fan ST, Bao H. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol. 2006;12:1292-1295. [PMID: 16534888 DOI: 10.3748/wjg.v12.i8.1292] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
33 Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol. 2013;19:6665-6678. [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
34 Tong MJ, Hsien C, Song JJ, Kao JH, Sun HE, Hsu L, Han SH, Durazo FA, Saab S, Blatt LM. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci. 2009;54:1337-1346. [PMID: 19242792 DOI: 10.1007/s10620-009-0747-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
35 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 137] [Article Influence: 23.7] [Reference Citation Analysis]
36 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
37 Xu X, Yue M, Jiang L, Deng X, Zhang Y, Zhang Y, Zhu D, Xiao W, Zhou Z, Yao W, Kong J, Yu X, Wei J. Genetic variants in human leukocyte antigen-DP influence both hepatitis C virus persistence and hepatitis C virus F protein generation in the Chinese Han population. Int J Mol Sci 2014;15:9826-43. [PMID: 24897020 DOI: 10.3390/ijms15069826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
38 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300-4308. [PMID: 18666317 DOI: 10.3748/wjg.14.4300] [Cited by in CrossRef: 398] [Cited by in F6Publishing: 366] [Article Influence: 30.6] [Reference Citation Analysis]
39 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 5.3] [Reference Citation Analysis]
40 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300-4308. [PMID: 18666317 DOI: 10.3748/wjg.v14.i27.4300] [Reference Citation Analysis]